Finance Watch: Market Struggles On Iran War, Jobs Data, Impacting Biopharma Stocks
Public Company Edition: Biopharma stocks soared in recent months, but concerns about war in Iran and the latest US jobs numbers are hurting share prices across industries. Financial outcomes remain mixed for drug developers, with some financings and some restructurings.
Scrip - March 6, 2026

Servier Adds To Rare Cancers Portfolio With Proposed Day One Buyout
For $2.5bn, the deal will bring Servier a pediatric glioma drug to sell alongside its own Voranigo, and an early-stage clinical pipeline in oncology.
Scrip - March 6, 2026

J&J’s Tecvayli/Darzalex Faspro Wins FDA Approval For Second-Line Myeloma
With J&J’s CAR-T Carvykti also approved for second-line disease, an oncologist told Scrip multiple factors will determine who gets which therapy option.
Scrip - March 6, 2026

Pipeline Watch: Nine Approvals And Fifteen Phase III Readouts
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Scrip - March 6, 2026

Zealand Shares Slide After Petrelintide Phase II Data Fails To Impress
While Petrelintide’s Phase II efficacy data came in below expectations, the amylin analog's potential tolerability benefits could help its case in an increasingly competitive obesity drug market.
Scrip - March 6, 2026

Executives On The Move: IDEAYA Biosciences Gets A New CDO From AbbVie 
Recent moves in the industry include changes at the top at Merck & Co., Daiichi Sankyo and Amber Therapeutics, plus Merck & Co. gets a new senior executive from Sanofi.
Scrip - March 6, 2026

China Grants Global-First Approval To cAMP-biased GLP-1R Agonist For Weight Loss
China has granted a world-first approval to a cAMP-biased GLP-1R agonist, Sciwind's ecnoglutide, for weight management, following convincing Phase III results.
Scrip - March 6, 2026

Qilu, Lynk Score Phase III Wins In China Cancer, Atopic Dermatitis Trials
Qilu’s bifunctional combo of PD-1 and CTLA-4 antibodies hits its marks in a Phase III cervical cancer trial, while Lynk’s JAK1 inhibitor logs similar win in atopic dermatitis.
Scrip - March 6, 2026

Global Medtech Guidance Tracker: February 2026
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Over 40 documents have been posted on the tracker since its last update.
Medtech Insight - March 6, 2026

Curve Biosciences Targets Liver Disease With ‘Whole-Body Intelligence’ Platform
Curve Biosciences is developing a technology that analyzes signals from blood and organs to monitor the progression of chronic disease. The first product is a blood test to monitor patients with liver cirrhosis at risk for liver cancer, the second for MASH.
Medtech Insight - March 6, 2026

FDA And Industry Agree To Hiring Levels Based On Prior MDUFA Commitment Letter
During MDUFA negotiations held Feb. 11, the medtech industry agreed to a proposal from the FDA to base its hiring commitments on MDUFA IV.
Medtech Insight - March 6, 2026

NVision Takes Quantum Imaging To Cambridge, Targets 20 Global Sites In 2026
NVision is pursuing regulatory clearance in the US, with trials launching across the US, Europe and Asia. In Europe, it is starting with Germany, Denmark, the UK and Italy before seeking broader EMA approval.
Medtech Insight - March 6, 2026

Reckitt Draws On VMS Strength To Offset Weak Cold & Flu Showing
Higher sales of dietary supplements in key markets like the US and China helped Reckitt's Self-Care business to grow in 2025 despite a weak cold & flu season.
HBW Insight - March 6, 2026

Sandoz Moves In On Canadian And Brazilian Semaglutide Opportunity
Sandoz says GLP-1s represent a long-term growth opportunity but warns the off-patent market will take time to develop, with early launches potentially coming in Canada and Brazil as the company tests supply dynamics and regulatory timelines.
Generics Bulletin - March 6, 2026

Affordable Medicines To Be Key Driver For Amneal In 2026 As Specialty Takes Back Seat
Even Amneal, a prominent off-patent player, is not immune to generic competition, as its Parkinson’s disease drug Rytary is expected to take a hit.
Generics Bulletin - March 6, 2026

Aspen Aiming ‘To Be In The Mix’ As Generic Semaglutide Reaches Canada Soon
Aspen Pharmacare is targeting early launches of generic semaglutide as patents begin to expire, aiming to be among the first entrants in Canada’s emerging market for GLP-1 rivals and using the approval as a springboard into emerging markets.
Generics Bulletin - March 6, 2026

The Autonomous Lab: Part 1
In this two-part series, In Vivo examines who is building the autonomous lab, what architectural and business model choices they are making, and what the implications are for drug discovery organizations, external R&D partnerships and the workforce that will be asked to operate these systems.
In Vivo - March 5, 2026